Mammalian skeletal muscles have an outstanding capacity to regenerate in response to damage. The muscle regeneration process includes coordinated steps of necrosis, inflammation and re-establishment of the structure and function of skeletal muscle tissue (Ciciliot & Schiaffino [@b16], Ten Broek *et al*. [@b63], Tsivitse [@b64]). After muscle damage, neutrophils are the inflammatory cells that initiate the invasion of the muscle tissue, followed by the classically activated or (M1) macrophages, which express CD86 and secrete pro-inflammatory cytokines, such as interleukin 1*β* (IL-1*β*), and inducible nitric oxide synthase (iNOS) (Locati *et al*. [@b35], Mantovani *et al*. [@b38]). Subsequently, there is a shift in phenotype from M1 to alternatively activated M2 macrophages, which express the mannose receptor (CD206) and secrete anti-inflammatory cytokines, such as arginase-1 and found in inflammatory zone 1 (Fizz1) (Locati *et al*. [@b35], Mantovani *et al*. [@b38]). Growth and repair of myofibres after injury are mediated by a resident population of mononuclear myogenic precursor cells, the satellite cells (SCs), which are small progenitor cells located between the basal lamina and the sarcolemma of individual muscle fibres (Ferrari *et al*. [@b21]). Following muscle injury, these cells divide and give rise to the SC progeny, the myoblasts, which fuse to each other to repair or replace damaged fibres (Blau *et al*. [@b6], Boldrin *et al*. [@b7]).

Although the morphological aspects of skeletal muscle regeneration are well known, the molecular players involved in this process have not been fully elucidated. Accordingly, the signalling pathways that regulate protein turnover are strongly modulated over the course of this process (Drummond *et al*. [@b20], Miyabara *et al*. [@b45]). The phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) pathway and the ubiquitin proteasome system exert an essential role in skeletal muscle mass recovery after damage (Stipanuk [@b61], Vary & Lynch [@b67], Ge *et al*. [@b22], Miyabara *et al*. [@b45]). Likewise, members of the transforming growth factor *β* (TGF-*β*) superfamily, such as myostatin, TGF-*β*1, TGF-*β*1 receptors (TGF-*β*-Rs), and their intracellular regulatory protein-receptor-regulated Smad2 and 3, and co-Smad, Smad4 are important to the success of muscle regenerative response (Droguett *et al*. [@b19], Zhu *et al*. [@b73]). Furthermore, more recent studies have suggested the involvement of other factors, such as Mustn1 and akirin1, in the regulation of skeletal muscle regeneration, considering that Mustn1 is highly expressed during myoblast fusion (Krause *et al*. [@b33]), and akirin1 is strongly induced in activated satellite cells and macrophages (Salerno *et al*. [@b57]). The *β*2-adrenoceptor may play an important role in muscle regeneration, as several studies have shown that *β*2-adrenergic stimulation, through muscle treatment with *β*2-adrenergic agonists, increases the size and strength recovery of regenerating myofibres (Beitzel *et al*. [@b4], [@b5], Bricout *et al*. [@b8], Ryall *et al*. [@b56], Conte *et al*. [@b17]).

Skeletal muscle contains a significant proportion of *β*-adrenoceptors, of which the *β*2-subtype is the most prevalent (90%) (Kim *et al*. [@b30]). *β*-adrenoceptors belong to the guanine nucleotide-binding G protein-coupled receptor (GPCR) family. The classical *β*2-adrenoceptor signalling pathway through G*α*-AC-cAMP activation is, at least in part, responsible for the *β*2-adrenoceptor-mediated hypertrophy in the skeletal muscle (Navegantes *et al*. [@b46], [@b47], Hinkle *et al*. [@b26]). Once activated, cAMP can interact with the exchange protein directly activated by cAMP (EPAC) through the small GTPase Rap1, which may trigger the PI3K/AKT/mTOR signalling pathway, resulting in increased protein synthesis (Lynch & Ryall [@b37]). In addition, activated cAMP can bind to protein kinase A, which phosphorylates calpastatin, leading to the inhibition of the proteolytic activity of the calpain enzymes (Lynch & Ryall [@b37]). Furthermore, the G*βγ* dimer seems to activate the PI3K/AKT/mTOR signalling pathway, thereby contributing to muscle hypertrophy (Kline *et al*. [@b32], Lynch & Ryall [@b37]).

Recently we have shown that *β*2-adrenergic stimulation, through formoterol treatment, is able to increase the size of regenerating myofibres in young and old rats through the activation of mTOR (Conte *et al*. [@b17]). In fact, previous studies have demonstrated that the *β*2-adrenergic agonists clenbuterol and fenoterol improved the recovery of myofibre size in regenerating skeletal muscles after transplantation (Roberts & McGeachie [@b53]) and muscle injury (Beitzel *et al*. [@b4], Bricout *et al*. [@b8]). Additionally, other studies have indicated that *β*2-adrenoceptor stimulation contributes to the increase in satellite cell proliferation and differentiation (Roberts & McGeachie [@b53], [@b54], Spurlock *et al*. [@b60]), enrichment of vascular repair (Roberts & McGeachie [@b54]), decrease in inflammation and a more efficient restoration of the extracellular matrix (Pullar *et al*. [@b52], Zhang *et al*. [@b71]). However, the role of the *β*2-adrenoceptor in skeletal muscle regenerative process and its importance to the muscle contractile recovery after injury is still unknown.

Considering that *β*2-adrenergic stimulation enhances the structural and functional repair of regenerating muscle, we hypothesized that the *β*2-adrenoceptor plays an important role in the skeletal muscle regenerative process. Therefore, this study aimed to investigate the role of the *β*2-adrenoceptor in histological, molecular and functional aspects of skeletal muscle regeneration of *β*2-adrenoceptor knockout (*β*~2~KO) mice. To attain this goal, we evaluated morphological and muscle contractile aspects, M1 and M2 macrophage profile, cAMP content, activation of TGF-*β* signalling elements \[TGF-*β* receptor I (T*β*R-I) and Smad2/3\], and akirin1 and Smad4 expression in regenerating TA muscles from *β*~2~KO mice.

Methods
=======

All protocols used in this study were in accordance with Good Publishing Practice in Physiology (Persson [@b51]).

Animals
-------

A cohort of male congenic Friend virus B-type (FVB) mouse strain lacking *β*2-adrenoceptor (*β*~2~KO) (Chruscinski *et al*. [@b15]) and their age-matched FVB wild type (WT) controls at 2 months of age were used in this study. Mice were maintained in standard housing conditions (Conte *et al*. [@b17]).

Experimental design
-------------------

In this study, one TA muscle (left hind limb) from each animal was subjected to cryolesion (Cryo group), and the contralateral TA muscle (right hind limb) was used as control (CL group). WT and *β*~2~KO animals were randomized into four groups for the histological experiments (*n* = 6, each group). Both WT and *β*~2~KO animals were subjected to cryolesion and were evaluated at 1, 3, 10 and 21 days post-cryolesion respectively. Contralateral muscles were designated as intact controls (CL group). In addition, distinct animals were used for the muscle contraction and cAMP quantification experiments and were evaluated at post-cryolesion day 10 (Conte *et al*. [@b17]).

Based on Pereira *et al*. ([@b50]), animals were anesthetized and had the superior surface of the TA muscle entirely exposed. The cryolesion procedure was performed according to Conte *et al*. ([@b17]), using the iron rod (flat end) dimensions of 2 × 9 mm and bringing it into contact with the muscle twice (i.e., in the two longitudinal halves of the muscle).

Histology
---------

Animals were killed by decapitation, after which their left and right TA muscles were removed, weighed and stored according to Pereira *et al*. ([@b50]). Muscle cross sections (10-*μ*m-thick) obtained from the TA middle-bellies were stained with an aqueous solution of toluidine blue and borax (Miyabara *et al*. [@b43]). Necrotic myofibres were localized by histochemical detection of lysosomal acid phosphatase activity (Gomori lead method) (Bancroft [@b3], Miyabara *et al*. [@b45]).

The stained sections were analysed in a Nikon Eclipse light microscope (PCM2000; Nikon, New York, NY, USA), and figures were prepared using A[dobe]{.smallcaps} P[hotoshop]{.smallcaps} 7.0 (Adobe Systems, San Jose, CA, USA).

Cyclic AMP (cAMP) quantification
--------------------------------

cAMP quantification was performed according to Conte *et al*. ([@b17]).

Antibodies for immunostaining
-----------------------------

The primary antibodies used for immunostaining were (1) mouse monoclonal anti-MAC387 (macrophage) (1 : 200; cat\# ab22506; Abcam, Cambridge, MA, USA), (2) rabbit polyclonal anti-TGF-*β* receptor I phospho S165 (cat\# ab112095, 1 : 250; Abcam) and (3) rabbit monoclonal anti-Smad2/3 (cat\# 8685; 1 : 200; Cell Signaling Technology, Danvers, MA, USA). The corresponding secondary antibodies used were (1) goat anti-mouse IgG-fluorescein isothiocyanate (FITC) (1 : 200; cat\# 115-095-166; Jackson ImmunoResearch Laboratories, Baltimore, PA, USA); and (2) goat anti-rabbit IgG-rhodamine (1 : 200; cat\# ab6718; Abcam).

Immunostaining
--------------

Muscle cross sections were immunostained according to Pereira *et al*. ([@b50]).

Photomicrographs of the stained sections were obtained using a fluorescence microscope equipped with a 20× magnification objective lens (Nikon, Eclipse E1000, ACT-1 version 2.2 or Observer D1; Zeiss; Jena, Germany), and with FITC, Rhoda mine and fura filters.

Antibodies for Western blotting
-------------------------------

The primary antibodies used for Western blotting were (1) rabbit polyclonal anti-Smad4 (1 : 1000; cat\# 9515; Cell Signaling Technology), (2) rabbit polyclonal anti-akirin1 (1 : 1000; cat\# ab77075; Abcam) and (3) rabbit polyclonal anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1 : 2000; cat\# ABS16; Millipore, Temecula, CA, USA). The corresponding secondary antibody used for all Western blots was peroxidase-conjugated AffiniPure goat anti-rabbit IgG (1 : 10 000; cat\# 111-035-003; Jackson Immuno Research Laboratories).

Western blot analysis
---------------------

Western blot analysis was executed according to Conte *et al*. ([@b17]). Densitometry analysis was performed based on Pereira *et al*. ([@b50]).

Gene expression analysis
------------------------

### Reverse transcription

Total RNA was isolated from muscle samples using Trizol reagent (Invitrogen, Carlsbad, CA, USA). Reverse transcription was performed according to Silva *et al*. ([@b59]).

### Primer design

The following primer sequences were used: Fizz-1: 5′-GAGACCATAGAGATTATCGTGGA-3′ forward, 5′-CACACCCAGTAGCAGTCATC-3′ reverse; Arginase-1: 5′-CAATGAAGAGCTGGCTGGTGT-3′ forward, 5′- GTGTGAGCATCCACCCAAATG-3′ reverse; iNOS: 5′-CTGCAGCACTTGGATCAG-3′ forward, 5′-CGTACCAGGCCCAATGAG-3′ reverse; IL-1*β*: 5′-CCAAAAGATGAAGGGCTGCTTCC-3′ forward, 5′-GGATGGGCTCTTCTTCAAAGATG-3′ reverse and TFIID: 5′-TTAGGCCTGGAAAGGTGTTACG-3′ forward, 5′-CCTCCAAACAGATGGAACATTCT-3′ reverse.

Primer sequences for Fizz-1, Arginase-1, iNOS were obtained from Villalta *et al*. ([@b68]) and primer sequences for IL-1*β* and the transcription factor IID (TFIID) were obtained from Acharyya *et al*. ([@b1]) and Silva *et al*. ([@b59]) respectively. The primers were synthesized from Exxtend Biotecnologia, Brazil.

### Real-time PCR

Real-time PCR was carried out on an ABI Prism 7300 Sequence detection system (QuantStudio™ 12K Flex Real-Time PCR System; Applied Biosystems, Foster City, CA, USA) according to Aoki *et al*. ([@b2]). The transcription factor TFIID was used as the housekeeping gene. Expression values are reported as fold difference relative to the expression of the control (calculated as ). The WT Cryo 1d group was used as control when no amplification was detected in WT CL group.

In addition to 3 and 10 days post-injury, the time point of day 1 was included in the gene expression analysis of the M1 and M2 macrophage markers, considering that M1 macrophages invade the wound site at 1 day post-damage (Turner & Badylak [@b66]).

Flow cytometry
--------------

Muscle samples underwent two enzymatic dissociations and, subsequently, the cells were filtered with a 40-*μ*m cell strainer (BD Biosciences, San Jose, CA, USA) (Cheung *et al*. [@b14]). Based on Larocca *et al*. ([@b34]), the filtrate was centrifuged at 600 ***g*** for 15 min and cells were resuspended in lyses buffer for erythrocytes removal. Cell pellets were resuspended in PBS supplemented with 2% foetal bovine serum and stained with the following antibodies at 1 : 100 dilution for 30 min at 4 °C in the dark: APC-Cy7-conjugated anti-CD11b, PE-conjugated anti-CD86 (for validation of M1 polarization) and APC-conjugated anti-CD206 (for validation of M2 polarization). At least 50 000 cells were acquired with BD FACSCanto II using the FACSD[iva]{.smallcaps} software (BD Biosciences). The data analysis was performed with F[low]{.smallcaps}J[o]{.smallcaps} software (Tree Star, Ashland, OR, USA). A gate for macrophages was set based on forward scatter (FSC) and CD11b positive. From this population, gates for CD86 and CD206 positive cells were created. Results were present as the percentage of positively stained cells within the cell population (macrophages gate) or macrophage population (CD86 and CD206 gates). The results are representative of 3 distinct experiments.

Mechanical measurements
-----------------------

Mechanical measurements in TA muscles were obtained according to Pereira *et al*. ([@b50]). Frequencies of isolated twitches, maximum tetanic contraction and tetanus during fatigue protocol were 0.2, 200 and 100 Hz respectively.

Quantitative and morphometric analyses
--------------------------------------

I[mage]{.smallcaps}P[ro]{.smallcaps} P[lus]{.smallcaps} software (Media Cybernetics, Silver Spring, MD, USA) was used for the quantitative and morphometric analyses.

Myofibre CSA was manually measured, and it was obtained from all regenerating myofibres with centralized nuclei in muscles analysed on post-cryolesion day 10 and 21 (Pereira *et al*. [@b50]).

Necrotic myofibres in three whole cross sections for each muscle (*n* = 3) stained with acid phosphatase and analysed on post-cryolesion day 1 were counted and expressed as the percentage of total myofibres.

Regenerating myofibres were counted and expressed as the percentage of total myofibres according to Conte *et al*. ([@b17]).

The areas of inflammation in the muscle cross sections stained with toluidine blue and analysed on post-cryolesion days 3 and 10 were measured and expressed as the percentage of the whole muscle cross section (*n* = 4 per group).

Macrophages were quantified based on Pereira *et al*. ([@b50]).

The T*β*R-I positive area and the number of nuclei positive for Smad2/3 were obtained from the injured muscle area of the whole muscle cross sections analysed at 3 days post-cryolesion (*n* = 3, each group). Subsequently, the injured area and the whole muscle cross-section area were measured. The T*β*R-I positive area was expressed as the percentage of the entire muscle cross section, and the incidence of Smad2/3 positive nuclei was expressed as the number of Smad2/3 positive nuclei per square millimetre.

Statistical analysis
--------------------

Multiple comparisons of mean values were performed according to Conte *et al*. ([@b17]). The unpaired *t*-test was used for comparisons between two groups (Miyabara *et al*. [@b45]). For all comparisons, *P* ≤ 0.05 was considered significant.

Results
=======

Body and muscle weights
-----------------------

The body weight of WT mice was not altered over the course of 21 days (Table [1](#tbl1){ref-type="table"}), whereas the body weight of *β*~2~KO mice increased 8% at 10 days and 12% at 21 days (*P* ≤ 0.05; Table [1](#tbl1){ref-type="table"}).

###### 

Comparison of body (BW, g) and muscle weight (MW, mg) from cryolesioned groups from wild-type (WT) and *β*2-adrenoceptor knockout (*β*~2~KO) mice

           Groups     C            Cryo 1d      Cryo 3d      Cryo 10d                                      Cryo 21d
  -------- ---------- ------------ ------------ ------------ --------------------------------------------- ---------------------------------------------
  BW (g)   WT         27.4 (1.3)   27.5 (1.3)   28.1 (0.8)   28.3 (1.4)                                    29.1 (1.4)
           *β*~2~KO   26.6 (1.2)   26.7 (1.2)   27.4 (1.2)   28.7 (1.8)[\*](#tf1-1){ref-type="table-fn"}   29.8 (2.0)[\*](#tf1-1){ref-type="table-fn"}

            Groups       CL 1d        Cryo 1d                                                                        CL 3d        Cryo 3d                                      CL 10d       Cryo 10d                                                                                                      CL 21d       Cryo 21d
  --------- ------------ ------------ ------------------------------------------------------------------------------ ------------ -------------------------------------------- ------------ ------------------------------------------------------------------------------------------------------------- ------------ ----------------------------------------------------------------------------
  MW (mg)   WT           36.6 (0.7)   53.8 (1.1)[\*](#tf1-1){ref-type="table-fn"}                                    36.6 (1.9)   38.6 (3.2)[a](#tf1-3){ref-type="table-fn"}   35.8 (0.8)   27.2 (2.0)[\*](#tf1-1){ref-type="table-fn"}[a](#tf1-3){ref-type="table-fn"}[b](#tf1-4){ref-type="table-fn"}   38.9 (1.8)   36.6 (1.3)[a](#tf1-3){ref-type="table-fn"}[c](#tf1-5){ref-type="table-fn"}
            *β*~*2*~KO   34.3 (1.0)   46.9 (2.5)[\*](#tf1-1){ref-type="table-fn"}[\#](#tf1-2){ref-type="table-fn"}   39.1 (1.0)   34.4 (3.9)[a](#tf1-3){ref-type="table-fn"}   39.0 (4.1)   34.0 (4.2)[\#](#tf1-2){ref-type="table-fn"}[a](#tf1-3){ref-type="table-fn"}                                   39.1 (1.1)   38.2 (2.3)[a](#tf1-3){ref-type="table-fn"}

Values are expressed as means and SD; *n* = 6. ANOVA followed by the Bonferroni\'s test for multiple comparisons was applied to test differences among the various groups. BW, body weight; MW, muscle weight; C, intact control, Cryo 1d, Cryo 3d, Cryo 10d, and Cryo 21d, cryolesioned and analysed after 1, 3, 10 and 21 days; CL, intact muscle from the contralateral leg, respectively.

*P* ≤ 0.05 vs. matched control or matched CL.

*P* ≤ 0.05 vs. the matched group from WT;

*P* ≤ 0.05 vs. Cryo 1d;

*P* ≤ 0.05 vs. Cryo 3d;

*P* ≤ 0.05 vs. Cryo 10d.

At 1 day post-cryolesion, muscle weight of both WT and *β*~2~KO mice increased, when compared with the respective contralateral group (47 and 37% respectively; *P* ≤ 0.05; Table [1](#tbl1){ref-type="table"}), but muscle weight of *β*~2~KO mice increased 13% less than that of WT mice, in the same period (*P* ≤ 0.05; Table [1](#tbl1){ref-type="table"}). On post-cryolesion day 3, muscle weight of both WT and *β*~2~KO mice decreased, when compared with muscles on post-cryolesion day 1 (28 and 27%, respectively, *P* ≤ 0.05; Table [1](#tbl1){ref-type="table"}). However, muscle weight was unchanged when compared to the respective contralateral groups (Table [1](#tbl1){ref-type="table"}).

When analysed at 10 days, muscle weight of WT mice decreased by 24%, when compared to its respective contralateral group (*P* ≤ 0.05; Table [1](#tbl1){ref-type="table"}), whereas it was unaltered in *β*~2~KO mice. On post-cryolesion day 21, muscle weight of WT mice increased by 35%, when compared with that on post-cryolesion day 10 (*P* ≤ 0.05; Table [1](#tbl1){ref-type="table"}), until it reached a value similar to the respective contralateral group (Table [1](#tbl1){ref-type="table"}). By contrast, muscle weight of *β*~2~KO mice remained unchanged at 10 and 21 days post-cryolesion (Table [1](#tbl1){ref-type="table"}).

Histology
---------

Histological cross sections of TA muscle samples collected on post-cryolesion days 1, 3, 10 and 21 were stained with toluidine blue and analysed by light microscopy. Intact contralateral muscles from both WT and *β*~2~KO mice exhibited polygonal fibres with peripheral nuclei, which is typical of normal tissue structure (Fig. [1](#fig01){ref-type="fig"}).

![(a) Representative toluidine blue stained tibialis anterior (TA) muscle cross sections of WT and *β*~2~KO mice. (a) WT contralateral group; (b) KO contralateral group*;* (c) WT, 1 day post-cryolesion; (d) *β*~2~KO, 1 day post-cryolesion; (e) WT, 3 days post-cryolesion; (f) *β*~2~KO, 3 days post-cryolesion; (g) WT, 10 days post-cryolesion; (h) *β*~2~KO, 10 days post-cryolesion; (i) WT, 21 days post-cryolesion; (j) *β*~2~KO, 21 days post-cryolesion. Arrows, hypercontracted fibres; asterisks, inflammatory cell infiltration; arrow head, cells with centralized nuclei; small arrows, split fibres. Bar: 50 *μ*m. (b) Comparison of percentage of necrotic myofibres in muscles from WT and *β*~2~KO mice at 1 day post-cryolesion (% of total myofibres from whole muscle CSA). Data are expressed as mean and SD; *n* = 3. (unpaired *t*-test). (c) Comparison of percentage of inflammatory area in muscles from WT and *β*~2~KO mice at 3 and 10 days post-cryolesion (% of whole muscle CSA). Data are expressed as mean and SD; *n* = 4. (analysis of variance followed by Bonferroni\'s test for multiple comparisons) ^\#^*P* ≤ 0.05 vs. WT mice; ^b^*p* ≤ 0.05 vs. Cryo 3d. (d) Frequency distribution of myofibre cross-sectional area (CSA) in contralateral and cryolesioned muscles from WT and *β*~2~KO mice analysed at 10 and 21 days post-cryolesion; *n* = 5. Kolmogorov--Smirnov test was applied in order to test differences between groups. (e) Comparison of percentage of centrally nucleated myofibres in muscles from WT and *β*~2~KO mice at 10 and 21 days post-cryolesion (% of total myofibres from whole muscle CSA). Data are expressed as mean and SD; *n* = 3. (analysis of variance followed by Bonferroni\'s test for multiple comparisons).](apha0211-0617-f1){#fig01}

Contralateral muscles from *β*~2~KO mice had slightly smaller myofibre CSAs when compared to muscles from WT mice, that is, 59% of myofibres were smaller than 2000 *μ*m^2^ in the contralateral *β*~2~KO group, whereas 54% of myofibres were smaller than 2000 *μ*m^2^ in the contralateral WT group (*P* ≤ 0.05; Fig. [1](#fig01){ref-type="fig"}).

On post-cryolesion day 1, tissue damage in both WT and *β*~2~KO mice was evident in freeze-injured TA muscles, as confirmed by the presence of hypercontracted fibres, inflammatory cell infiltration and clear spaces between the cells, indicating myonecrosis, tissue disruption and oedema (Fig. [1](#fig01){ref-type="fig"}). In addition, the percentage of necrotic myofibres in muscles analysed on post-cryolesion day 1 from both WT and *β*~2~KO mice was similar (43 ± 9 and 44 ± 11%, respectively, Fig. [1](#fig01){ref-type="fig"}).

At 3 days post-cryolesion, a small inflammatory area was evident in muscles from both WT and *β*~2~KO mice (18 ± 3 and 25 ± 4% of the entire muscle cross section, respectively, Fig. [1](#fig01){ref-type="fig"}), with a tendency of increase in muscles from *β*~2~KO mice compared to those from WT mice (Fig. [1](#fig01){ref-type="fig"}). Hypercontractured myofibres were also observed in *β*~2~KO mice (Fig. [1](#fig01){ref-type="fig"}), suggesting the persistence of acute signs of injury.

At 10 days post-cryolesion, 69.5% of myofibres containing central nuclei from WT mice were smaller than 1200 *μ*m^2^, against only 15% in the contralateral group (*P* ≤ 0.05; Fig. [1](#fig01){ref-type="fig"}). Additionally, the regenerating muscles from WT group showed split fibres. At the same time point, regenerating myofibres with central nuclei from *β*~2~KO mice were smaller than those from the contralateral group (74% were smaller than 1200 *μ*m^2^ in the *β*~2~KO group, against 21% in the contralateral group, *P* ≤ 0.05; Fig. [1](#fig01){ref-type="fig"}) and from WT mice (54% in *β*~2~KO vs. 62% in WT, with CSA values between 400 and 1200 *μ*m^2^ respectively; *P* ≤ 0.05; Fig. [1](#fig01){ref-type="fig"}). Also, muscles from the *β*~2~KO group exhibited typical signs of acute lesion, such as hypercontracted fibres and inflammatory infiltration, which was larger compared to that from the WT group (254%, *P* ≤ 0.05; Fig. [1](#fig01){ref-type="fig"}). In addition, the area of inflammation increased in muscles from the *β*~2~KO group analysed on post-cryolesion day 10, when compared to those analysed on post-cryolesion day 3 (47%, *P* ≤ 0.05; Fig. [1](#fig01){ref-type="fig"}). However, the area of inflammation was unchanged in the WT group (Fig. [1](#fig01){ref-type="fig"}).

On post-cryolesion day 21, TA muscles from freeze-injured WT mice were completely regenerated, as evidenced by the classical signs of regeneration (Karpati *et al*. [@b28]), that is, restored myofibres with centralized nuclei, CSA values similar to contralateral muscles, as well as split fibres (Fig. [1](#fig01){ref-type="fig"}). At this same time point, regenerating myofibres from *β*~2~KO mice were larger than those from the Cryo 10d group (74% were larger than 1200 *μ*m^2^ in the *β*~2~KO group, *P* ≤ 0.05; Fig. [1](#fig01){ref-type="fig"}) and from WT mice (74% were larger than 1200 *μ*m^2^ in the *β*~2~KO group, *P* ≤ 0.05; Fig. [1](#fig01){ref-type="fig"}). In addition, cryolesioned muscles analysed at 21 days post-injury from *β*~2~KO mice had regenerating myofibres with centralized nuclei with similar calibre size, when compared to those from WT mice (Fig. [1](#fig01){ref-type="fig"}).

The percentage of regenerating myofibres with centralized nuclei was unaltered in the groups analysed on post-cryolesion days 10 and 21 (Fig. [1](#fig01){ref-type="fig"}).

Total number of macrophages and muscle macrophage phenotype
-----------------------------------------------------------

### Incidence of Mac387 positive macrophages

At 3 and 10 days post-cryolesion, the number of macrophages in muscles from WT and *β*~2~KO mice increased when compared to the respective controls (WT: 4978 and 3988% respectively; *β*~2~KO: 10 038 and 8572% respectively; *P* ≤ 0.05; [Fig. 2](#fig02){ref-type="fig"}). In addition, at 3 and 10 days post-cryolesion, the number of macrophages in muscles from *β*~2~KO mice was 157 and 173% higher than that observed in muscles from WT mice respectively (*P* ≤ 0.05; Fig. [2](#fig02){ref-type="fig"}).

![Incidence of macrophages per cubic millimetre (mm^3^) of contralateral (CL) muscles and injured muscles analysed on post-cryolesion days 3 and 10 (Cryo 3d; Cryo 10d) from WT and *β*~2~KO mice. Data are expressed as mean and SD; *n* = 3. (analysis of variance followed by Bonferroni\'s test for multiple comparisons) \**P* ≤ 0.05 vs. CL; ^\#^*P* ≤ 0.05 vs. WT mice.](apha0211-0617-f2){#fig02}

### M1 and M2 associated genes

Gene expression of IL-1*β* and arginase-1 did not change in all groups evaluated (Fig[3](#fig03){ref-type="fig"}).

![iNOS (a) IL-1*β*, (b) arginase-1, (c) fizz-1 and (d) gene expression analysed 1, 3 and 10 days after cryolesion in WT and *β*~2~KO mice. Values are expressed as mean and SD; *n* = 4--5 (analysis of variance followed by Bonferroni\'s test for multiple comparisons) \**P* ≤ 0.05 vs. matched CL; ^\#^*P* ≤ 0.05 vs. matched WT group; ^a^*p* ≤ 0.05 vs. Cryo 1d.](apha0211-0617-f3){#fig03}

iNOS mRNA expression did not change in muscles from WT group evaluated at 1, 3 and 10 days post-cryolesion, when compared to the respective contralateral muscles (Fig[3](#fig03){ref-type="fig"}). On day 1 post-cryolesion, iNOS mRNA expression in muscles from *β*~2~KO group increased 705% when compared to that of the contralateral muscles, and 1116% when compared to that from WT group, evaluated in the same time point post-injury (*P* ≤ 0.05; Fig. [3](#fig03){ref-type="fig"}). By contrast, iNOS mRNA expression in muscles from *β*~2~KO group decreased at 3 and 10 days post-cryolesion when compared to that obtained on day 1 post-cryolesion (89 and 82% respectively; *P* ≤ 0.05; Fig. [3](#fig03){ref-type="fig"}).

Fizz-1 mRNA expression was unaltered in muscles from WT group in all time points analysed (Fig. [3](#fig03){ref-type="fig"}). Fizz-1 mRNA expression increased in the contralateral muscles from *β*~2~KO group, when compared to that from the contralateral muscles from WT group (1238%, *P* ≤ 0.05; Fig. [3](#fig03){ref-type="fig"}). By contrast, Fizz-1 mRNA expression decreased in the injured muscles at 1, 3 and 10 days post-injury when compared to that obtained in the contralateral muscles from *β*~2~KO group (96, 99 and 92%, respectively, *P* ≤ 0.05, Fig. [3](#fig03){ref-type="fig"}).

### CD11b^+ve^, CD86^+ve^ and CD206^+ve^ cell population

The CD11b^+ve^ population increased in regenerating muscles from both WT and *β*~2~KO mice analysed at 3 and 10 days when compared to the respective controls (WT: 557 and 286% respectively; *P* ≤ 0.05; *β*~2~KO: 459 and 419%, respectively, *P* ≤ 0.05; Fig. [4](#fig04){ref-type="fig"}), and this increase was more pronounced in muscles from *β*~2~KO mice when analysed at 3 days (46%, *P* ≤ 0.05; Fig. [4](#fig04){ref-type="fig"}), but not at 10 days.

![CD11b^+ve^, CD86^+ve^ and CD206^+ve^ cell population. (a) Percentage of CD11b^+ve^ population, CD86^+ve^ and CD206^+ve^ cells in the CD11b^+ve^ population in contralateral and injured muscles analysed at 3 days from both WT and *β*~2~KO mice. (b) Percentage of CD11b^+ve^ population, CD86^+ve^ and CD206^+ve^ cells in the CD11b^+ve^ population in contralateral and injured muscles analysed at 10 days from both WT and *β*~2~KO mice. Values are expressed as mean and SD; *n* = 3--5 (analysis of variance followed by Bonferroni\'s test for multiple comparisons) \**P* ≤ 0.05 vs. CL; ^\#^*P* ≤ 0.05 vs. WT mice.](apha0211-0617-f4){#fig04}

The percentage of CD86^+ve^ cells in the CD11b^+ve^ population in muscles from WT and *β*~2~KO mice analysed at 3 and 10 days did not change in any of the groups evaluated. However, the percentage of CD86^+ve^ cells tended to increase in the CD11b^+ve^ population in regenerating muscles from *β*~2~KO mice, when compared to those from WT mice at the same time point evaluated (Fig. [4](#fig04){ref-type="fig"}).

The percentage of CD206^+ve^ cells in the CD11b^+ve^ population in regenerating muscles from WT and *β*~2~KO mice analysed at 3 and 10 days decreased when compared to the respective contralateral muscles (WT: 96 and 50% respectively; *P* ≤ 0.05; *β*~2~KO: 94 and 47%, respectively, *P* ≤ 0.05; Fig. [4](#fig04){ref-type="fig"}).

Activation of TβR-I/Smad2/3
---------------------------

With regard to the immunostaining against T*β*R-I, contralateral muscles from both WT and *β*~2~KO mice did not present immunopositivity for T*β*R-I (data not shown). The area positive for T*β*R-I in injured muscles from *β*~2~KO mice was 64% smaller than that from WT mice at the same time point evaluated (*P* ≤ 0.05; Fig. [5](#fig05){ref-type="fig"}). Similarly, nuclei positive for Smad2/3 were not observed in contralateral muscles from either WT or *β*~2~KO mice (data not shown). Also, at 3 days post-cryolesion, 28% fewer nuclei were positive for Smad2/3 in muscles from *β*~2~KO mice, compared to muscles from WT mice at the same time point evaluated (*P* ≤ 0.05; Fig. [6](#fig06){ref-type="fig"}).

![Active/phosphorylated T*β*R-I positive areas in muscle cross sections. (a) Immunostaining for active/phosphorylated T*β*R-I in tibialis anterior (TA) muscle cross sections. TA muscles from WT and *β*~2~KO mice at 3 days post-cryolesion. (a and d) DAPI (blue; stained nuclei) in muscles from WT and *β*~2~KO mice respectively; (b and e) muscles immunostained for phosphorylated T*β*R-I (red; TGF-*β* RI) from WT and *β*~2~KO mice respectively; (c and f) co-staining for TGF-*β* RI and DAPI in muscles from WT and *β*~2~KO mice respectively. Arrow heads indicate muscle areas immunopositive for phosphorylated T*β*R-I. (b) Comparison of percentage of activated/phosphorylated T*β*R-I positive muscle cross-sectional areas (% of whole muscle CSA) in contralateral muscles (CL) and regenerating muscles at 3 days post-cryolesion (Cryo 3d) in WT and *β*~2~KO mice. Data are expressed as mean and SD; *n* = 3 (analysis of variance followed by Bonferroni\'s test for multiple comparisons) ^\#^*P* ≤ 0.05 vs. WT mice.](apha0211-0617-f5){#fig05}

![Smad2/3 positive nuclei in muscle cross sections. (a) Immunostaining for Smad2/3 positive nuclei (active Smad2/3) in TA muscle cross sections. TA muscles from WT and *β*~2~KO mice at 3 days post-cryolesion. (a and d) DAPI (blue; stained nuclei) in muscles from WT and *β*~2~KO mice respectively; (b and e) muscles immunostained for Smad2/3 (red; Smad2/3) from WT and *β*~2~KO mice respectively; (c and f) co-staining for active Smad2/3 and DAPI in muscles from WT and *β*~2~KO mice respectively. Arrow heads indicate Smad2/3 positive nuclei. (b) Incidence of Smad2/3 positive nuclei per square millimetre (mm^2^) of contralateral muscles and muscles analysed on post-cryolesion day 3 in WT and *β*~2~KO mice. Data are expressed as mean and SD; *n* = 3 (analysis of variance followed by Bonferroni\'s test for multiple comparisons) ^\#^*P* ≤ 0.05 vs. WT mice.](apha0211-0617-f6){#fig06}

Smad4 and akirin1 expression in regenerating muscles
----------------------------------------------------

At 3 days post-cryolesion, Smad4 expression decreased in injured muscles from WT and *β*~2~KO mice when compared to their controls (25 and 41% respectively; *P* ≤ 0.05; Fig. [7](#fig07){ref-type="fig"}) and this decrease was more pronounced in muscles from *β*~2~KO mice when compared to those from WT group (32%; *P* ≤ 0.05; Fig. [7](#fig07){ref-type="fig"}). At 10 days post-cryolesion, Smad4 expression decreased at the same rate in injured muscles from both WT and *β*~2~KO mice, when compared to their controls (29 and 25% respectively; *P* ≤ 0.05; Fig. [7](#fig07){ref-type="fig"}). Moreover, the Smad4 expression in contralateral muscle from *β*~2~KO mice decreased when compared to contralateral muscle from WT group (24%; *P* ≤ 0.05; Fig. [7](#fig07){ref-type="fig"}).

![Smad4 and akirin1 expression. (a) Representative Western blots of contralateral muscles (CL) and injured muscles analysed on post-cryolesion days 3 and 10 (Cryo 3d; Cryo 10d) from WT and *β*~2~KO mice. Blots (50 *μ*g per lane) were reacted with antibodies specific to Smad4 and akirin1 (7 and 12% SDS-PAGE gels respectively), and subsequently with antibody to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which was used as standard. MW, molecular weight. (b) Densitometry analyses of Smad4 and akirin1. Data are presented as mean and SD of arbitrary unit (A.U.). *n* = 3 (analysis of variance followed by Bonferroni\'s test for multiple comparisons). \**P* ≤ 0.05 vs. CL; ^\#^*P* ≤ 0.05 vs. WT mice.](apha0211-0617-f7){#fig07}

Akirin1 expression was not detected in contralateral muscles from either WT or *β*~2~KO groups (Fig. [7](#fig07){ref-type="fig"}), but it was highly expressed at 10 days post-cryolesion in muscles from WT and *β*~2~KO mice when compared to their respective controls (1931 and 2387% respectively; *P* ≤ 0.05; Fig. [7](#fig07){ref-type="fig"}). In addition, the akirin1 expression in injured muscle from *β*~2~KO mice analysed on post-cryolesion day 10 was more robust when compared with that in injured muscles from WT mice (95%; *P* ≤ 0.05; Fig. [7](#fig07){ref-type="fig"}).

cAMP levels in regenerating muscles
-----------------------------------

We investigated whether disruption of the *β*2-adrenoceptor gene target would decrease cAMP levels in contralateral and injured muscles and whether cryolesion by itself would change such levels in muscles from both WT and *β*~2~KO mice. No changes were observed in cAMP levels in contralateral muscles from WT and *β*~2~KO mice (Fig. [8](#fig08){ref-type="fig"}). As expected, cryolesion alone induced a 228% increase in cAMP levels in muscles from WT mice after 10 days, when compared to their controls (*P* ≤ 0.05; Fig. [8](#fig08){ref-type="fig"}). In addition, the increase in cAMP levels was attenuated in TA muscles from *β*~2~KO mice at the same time point, when compared to their controls (125%, *P* ≤ 0.05; Fig. [8](#fig08){ref-type="fig"}).

![cAMP levels analysed 10 days after cryolesion in WT and *β*~2~KO mice. Data are mean and SD (*n* = 7 muscles per group). CL, contralateral muscle; Cryo, muscle analysed on post-cryolesion day 10. \**P* ≤ 0.05 vs. matched CL; ^\#^*P* ≤ 0.05 vs. matched WT group (analysis of variance followed by Bonferroni\'s test for multiple comparisons).](apha0211-0617-f8){#fig08}

Maximum tetanic and specific forces, and resistance to fatigue
--------------------------------------------------------------

The influence of the *β*2-adrenoceptor on the functional recovery of freeze-injured muscles was evaluated through the analysis of *in vivo* muscle contraction measurements on post-cryolesion day 10.

At the pre-fatigue tetanic contraction measurement, the absolute and specific force decreased by 34 and 43%, respectively, in the cryolesioned muscles from WT mice, when compared to the contralateral muscles from WT mice (*P* ≤ 0.05, Fig. [9](#fig09){ref-type="fig"}). Likewise, the tetanic force and specific force decreased by 43 and 27%, respectively, in the injured muscles from *β*~2~KO mice, when compared to the contralateral muscles from *β*~2~KO mice (*P* ≤ 0.05, Fig. [9](#fig09){ref-type="fig"}). Contralateral muscles from *β*~2~KO mice showed a 17% decrease in absolute force and a 29% decrease in specific force, when compared to those from WT mice (*P* ≤ 0.05, Fig. [9](#fig09){ref-type="fig"}). Similarly, injured muscles from *β*~2~KO mice showed 18% lower tetanic force and 17% lower specific force, compared to those from WT mice (*P* ≤ 0.05, Fig. [9](#fig09){ref-type="fig"}).

![Contractile measurements. (a) Comparison of maximum tetanic force (mN) and (b) specific force in contralateral and cryolesion muscles from WT and *β*~2~KO mice analysed on post-cryolesion day 10. CL, contralateral muscle; Cryo, cryolesioned muscle. Data are expressed as mean and SD; *n* = 8. \**P* ≤ 0.05 vs. matched CL; ^\#^*P* ≤ 0.05 vs. matched WT group; ^a^*p* ≤ 0.05 vs. matched 1 (analysis of variance followed by Bonferroni\'s test for multiple comparisons). (c) Force production of muscles from WT and *β*~2~KO mice analysed on post-cryolesion day 10 during a protocol of 10 contractions. CL, contralateral muscle; Cryo, cryolesioned muscle. Values are expressed as mean and SD; *n* = 8. \**P* ≤ 0.05 vs. matched CL; ^\#^*P* ≤ 0.05 vs. matched WT group; ^a^*p* ≤ 0.05 vs. the 1st tetanic contraction (mixed models for repeated measures).](apha0211-0617-f9){#fig09}

Regarding the post-fatigue tetanic and specific forces, we observed a reduction in tetanic and specific forces in injured TA muscles from WT and *β*~2~KO mice when compared to their controls (WT mice: 42 and 40% respectively; *β*~2~KO mice: 43 and 24% respectively; *P* ≤ 0.05, Fig. [9](#fig09){ref-type="fig"}). Similarly to the pre-fatigue tetanic contraction measurement, contralateral and injured muscles from *β*~2~KO mice showed lower tetanic and specific force, when compared to those from WT mice (contralateral muscles: 24 and 34% decrease respectively; cryolesioned muscles: 26 and 16% decrease respectively; *P* ≤ 0.05, Fig. [9](#fig09){ref-type="fig"}).

The post-fatigue tetanic and post-fatigue specific forces decreased, when compared to the pre-fatigue tetanic and pre-fatigue specific forces, in both WT and *β*~2~KO mice (contralateral muscles from WT mice: 11 and 9% decrease respectively; cryolesioned muscles from WT mice: 10 and 13% decrease respectively; contralateral muscles from *β*~2~KO mice: 20 and 16% decrease respectively; cryolesioned muscles from *β*~2~KO mice: 19 and 13% decrease respectively; *P* ≤ 0.05, Fig. [9](#fig09){ref-type="fig"}).

Tibialis anterior muscle strength was measured at four time points during the fatigue protocol (1st, 4th, 7th and 10th contractions). In contralateral muscles from both WT and *β*~2~KO mice, there was a significant loss of muscle strength beginning at the 4th contraction stimulus of the fatigue protocol (a 12 and 11% decrease in comparison to the 1st contraction respectively), and that difference persisted up to the 10th contraction (*P* ≤ 0.05, Fig. [9](#fig09){ref-type="fig"}). Also, muscle strength at the 1st contraction was significantly lower in the Cryo group than in the contralateral group from both WT and *β*~2~KO mice (39 and 45%, respectively; *P* ≤ 0.05, Fig. [9](#fig09){ref-type="fig"}). In the Cryo group from WT and *β*~2~KO mice, muscle strength was also significantly lower at the 4th, 7th and 10th contractions, in comparison with the 1st contraction (WT: 13, 18 and 77% respectively; *β*~2~KO: 11, 19 and 25% respectively*; P* ≤ 0.05, Fig. [9](#fig09){ref-type="fig"}). In addition, strength in contralateral and cryolesioned muscles from *β*~2~KO mice decreased when compared to the respective contralateral and cryolesioned muscles from WT mice at all time points (1st, 4th, 7th and 10th) evaluated (CL: 17, 16, 15 and 38% respectively; Cryo: 25, 24, 27 and 27% respectively; *P* ≤ 0.05, Fig. [9](#fig09){ref-type="fig"}).

Discussion
==========

Skeletal muscle regeneration is a crucial process responsible for the recovery and maintenance of muscle mass and function. The present study indicated that the *β*2-adrenoceptor was an important player in this process, as mice lacking this receptor had structural and functional impairments in skeletal muscle regeneration. The time points of 1, 3, 10 and 21 days post-injury were assessed because they represent important phases of skeletal muscle adaptation to injury, including intense necrosis and oedema, inflammation and satellite cell proliferation, evident regeneration with the reestablishment of myofibril proteins, and restoration of the structural and functional features of the skeletal muscle respectively (Hawke & Garry [@b25], Miyabara *et al*. [@b44]).

Initially, a gain in body weight was observed in *β*~2~KO mice compared to WT mice, suggesting that the *β*2-adrenoceptor contributed to the regulation of body weight. Notably, this finding is in line with previous studies indicating that *β*2-adrenergic stimulation causes lipolysis (Louis *et al*. [@b36], Hinkle *et al*. [@b26], Zhang *et al*. [@b70], Lynch & Ryall [@b37], Kim & Kong [@b29], Kim *et al*. [@b31]) and aids in glucose uptake in brown adipocytes from rodents (Marette & Bukowiecki [@b39], Shimizu *et al*. [@b58], Chernogubova *et al*. [@b13]). The *β*2-adrenergic agonists are known to induce lipolysis through the activation of G*α*-AC-cAMP followed by protein kinase A-mediated phosphorylation of adipose triglyceride lipase, hormone-sensitive-lipase and lipid-bound protein perilipin A; which result in increased hydrolysis of triacylglycerol, diacylglycerol and monoacylglycerol, and the release of free fatty acids from adipocytes (Holm [@b27], Pagnon *et al*. [@b48]). Therefore, the absence of *β*2-adrenoceptor may contribute to fat mass accumulation.

With regard to muscle weight, it is interesting to note that *β*~2~KO mice gained less muscle weight at 1 day post-injury, compared to WT mice, which may be related to a delay in the installation of oedema and inflammation that persisted for 10 days. In agreement with that, other studies have shown that *β*2-adrenoceptor stimulation induces a reduction in inflammation and a better remodelling of the extracellular matrix (Pullar *et al*. [@b52], Zhang *et al*. [@b71]) Therefore, it is probable that the *β*2-adrenoceptor regulates the inflammatory process. In fact, there was a more pronounced increase in the area of inflammation and in the number of macrophages in regenerating muscles lacking the *β*2-adrenoceptor, which led us to investigate possible mechanisms involved in the recruitment of inflammatory cells during muscle regenerative process. In this respect, our data suggest that, in the absence of the *β*2-adrenoceptor, there might be an increase in the frequency of M1 macrophages in regenerating muscles, indicated by a robust increase in iNOS gene expression at 1 day post-injury and a tendency of increase in the number of CD86^+ve^ cells at 3 and 10 days post-injury, which could delay the shift in M1 to M2 macrophage phenotype, and consequently delay the muscle regenerative process. In fact, the shift in M1 to M2 macrophage phenotype is essential for the progression of myogenic differentiation and muscle regeneration (Tsujinaka *et al*. [@b65], Szalay *et al*. [@b62], Wang *et al*. [@b69]).

One possible mechanism involved in the shift of M1 to M2 phenotype through the *β*2-adrenoceptor is through cAMP production (Panina-Bordignon *et al*. [@b49], Guereschi *et al*. [@b23]). Accordingly our results indicate that the increase in cAMP levels was attenuated in regenerating myofibres lacking the *β*2-adrenoceptor. However, the downstream signalling mechanisms are not well understood. Another possibility could involve the transactivation of T*β*R-I by the *β*2-adrenoceptor. More specifically, it is known that GPCRs are able to trans-activate serine/threonine kinase receptors (Burch *et al*. [@b9]), and that akirin1 is a target gene for serine/threonine kinase receptor stimulation (Marshall *et al*. [@b40], Salerno *et al*. [@b57], Dong *et al*. [@b18]). Therefore, we hypothesized that the absence of the *β*2-adrenoceptor might inhibit the transactivation of T*β*R-I, and subsequently inhibit its downstream targets, the Smad proteins, which could ultimately lead to increased akirin1 transcription. In fact, we observed a reduced activation of T*β*R-I and Smad2/3 and a decreased Smad4 expression in regenerating muscles lacking the *β*2-adrenoceptor at 3 days post-cryolesion. As a consequence, there was a more pronounced increase in the expression of akirin1, a macrophage chemoattractant, in regenerating muscles lacking the *β*2-adrenoceptor at 10 days post-cryolesion.

Akirin1 expression in macrophages, as well as its chemotactic properties in these cells (Salerno *et al*. [@b57]), could explain, at least in part, the increased macrophage density and persistence in regenerating muscles lacking the *β*2-adrenoceptor 10 days post-injury. Akirin1 is also involved in other phases of muscle regeneration and is upregulated in activated satellite cells and in regenerating myofibres (Salerno *et al*. [@b57]). In addition, akirin1 has been shown to induce post-mitotic differentiation and myotube hypertrophy (Marshall *et al*. [@b40]), which is in line with our findings on the increased akirin1 expression at 10 days post-cryolesion. Therefore, a higher expression of akirin1 in regenerating muscles lacking the *β*2-adrenoceptor could also serve as a compensatory mechanism, favouring the muscle regenerative response.

The increase in myofibre size during muscle regeneration seemed to be partially regulated by the *β*2-adrenoceptor, as demonstrated by a moderate reduction in the calibre of regenerating myofibres from *β*~2~KO mice at 10 days post-cryolesion, when compared to those from WT mice. This result might be explained, to some extent, by the attenuated increase in cAMP levels in regenerating muscles lacking the *β*2-adrenoceptor. Remarkably, this finding agreed with previous reports indicating that *β*2-adrenergic stimulation by muscle treatment with *β*2-agonists after injury led to an increase in both muscular cAMP levels and myofibre calibre (Roberts & McGeachie [@b53], Beitzel *et al*. [@b4], [@b5], Bricout *et al*. [@b8], Conte *et al*. [@b17]), and these effects could be reversed by the *β*2-antagonist ICI-118551 (Zhong *et al*. [@b72], McCormick *et al*. [@b41]).

With regard to the muscle contraction results, the decreased contractile function in muscles from *β*2KO mice may be due to impaired contractile mechanisms caused by the absence of the *β*2-adrenoceptor, rather than to a higher susceptibility to muscle damage, as the *β*2KO mice had the number of necrotic myofibres similar to those from WT mice. In line with our data, a study indicated that the stimulation of the Na^+^ -- K^+^ pump with the *β*2-adrenoceptor agonist salbutamol, epinephrine, rat calcitonin gene-related peptide (rCGRP), or dibutyryl cAMP, improved force recovery by 40--90% (Mikkelsen *et al*. [@b42]). In addition, it is known that the *β*2-adrenergic agonist terbutaline potentiates peak twitch and tetanic force in rat soleus myofibres, which is related to an increase in intracellular free Ca^2+^ (\[Ca^2+^\]~i~) (Ha *et al*. [@b24]). Considering that this effect is consistent with a mechanism whereby terbutaline activates *β*2-adrenoceptors leading to the protein kinase A-dependent phosphorylation of ryanodine receptor (Ha *et al*. [@b24]) with consequent increase in \[Ca^2+^\]~i~ (Cairns *et al*. [@b11]) and that terbutaline\'s effect on myofibre force is blocked by the *β*2-adrenoceptor antagonist ICI 118551; the decreased absolute and specific tetanic forces found in the TA muscles lacking the *β*2-adrenoceptor may occur due to an attenuation of protein kinase A-dependent phosphorylation of ryanodine receptor.

The lack of the *β*2-adrenoceptor, combined with cryolesion, led to much less muscle force production, which might be a consequence of attenuated increase in \[Ca^2+^\]~i~ associated with poor muscle mass recovery in regenerating myofibres under the absence of the *β*2-adrenoceptor. Muscles lacking the *β*2-adrenoceptor on post-cryolesion day 10 exhibited a larger area of inflammation and smaller-sized regenerating myofibres compared to those from WT mice. Therefore, it is reasonable to suggest that these muscles contained fewer myofibril components, thereby contributing to the reduction of force output. In line with the effects caused by the absence of *β*2-adrenoceptors in regenerating skeletal muscle, we have demonstrated that the *β*2-adrenergic stimulation through formoterol treatment is able to decrease the number of inflammatory cells in regenerating muscles, increase the size of regenerating myofibres, and consequently increase muscle force (Conte *et al*. [@b17]). In addition, previous studies have also claimed that *β*2-adrenoceptor stimulation led to improved muscle force generation after injury (Beitzel *et al*. [@b4], Ryall *et al*. [@b56]), which reinforces the hypothesis that the *β*2-adrenoceptor has a functional importance in muscle regenerative process.

Since there was no difference in the myofibre CSA from *β*~2~KO and WT mice on post-cryolesion day 21, we did not measure muscle function in this time point. Considering that the structure and function of regenerating muscles from *β*~2~KO mice analysed on post-cryolesion day 21 were probably similar to their non-injured contralateral muscles, the *β*2-adrenoceptor may be involved in the regulation of early phases of the muscle regenerative process, such as inflammation and recovery of myofibre size, and through unknown mechanisms, the delay in these early stages may be compensated.

In summary, this work demonstrates that the *β*2-adrenoceptor contributes to early stages of muscle regeneration, being particularly involved in the regulation of macrophage recruitment to the regenerating skeletal muscle tissue, possibly through activation of T*β*R-I and Smad2/3 as well as a reduction in akirin1 expression. Therefore, the *β*2-adrenoceptor may be an important clinical target for therapeutic interventions with pharmacological agents and gene therapy, with an aim to accelerate the initial phases following muscle injury, and consequently improve recovery and decrease the rehabilitation period in several conditions, such as sports injuries and the damage caused by surgical procedures, accident and frostbite.
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